352 related articles for article (PubMed ID: 17628166)
1. Doxorubicin delivery by polyamidoamine dendrimer conjugation and photochemical internalization for cancer therapy.
Lai PS; Lou PJ; Peng CL; Pai CL; Yen WN; Huang MY; Young TH; Shieh MJ
J Control Release; 2007 Sep; 122(1):39-46. PubMed ID: 17628166
[TBL] [Abstract][Full Text] [Related]
2. Enhanced cytotoxicity of saporin by polyamidoamine dendrimer conjugation and photochemical internalization.
Lai PS; Pai CL; Peng CL; Shieh MJ; Berg K; Lou PJ
J Biomed Mater Res A; 2008 Oct; 87(1):147-55. PubMed ID: 18085655
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin.
Xiong XB; Ma Z; Lai R; Lavasanifar A
Biomaterials; 2010 Feb; 31(4):757-68. PubMed ID: 19818492
[TBL] [Abstract][Full Text] [Related]
4. Comparative studies of polyethylenimine-doxorubicin conjugates with pH-sensitive and pH-insensitive linkers.
Dong DW; Tong SW; Qi XR
J Biomed Mater Res A; 2013 May; 101(5):1336-44. PubMed ID: 23065848
[TBL] [Abstract][Full Text] [Related]
5. Amphiphilic multi-arm-block copolymer conjugated with doxorubicin via pH-sensitive hydrazone bond for tumor-targeted drug delivery.
Prabaharan M; Grailer JJ; Pilla S; Steeber DA; Gong S
Biomaterials; 2009 Oct; 30(29):5757-66. PubMed ID: 19643472
[TBL] [Abstract][Full Text] [Related]
6. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
Han L; Huang R; Liu S; Huang S; Jiang C
Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
[TBL] [Abstract][Full Text] [Related]
7. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.
Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY
J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167
[TBL] [Abstract][Full Text] [Related]
8. Novel folated and non-folated pullulan bioconjugates for anticancer drug delivery.
Scomparin A; Salmaso S; Bersani S; Satchi-Fainaro R; Caliceti P
Eur J Pharm Sci; 2011 Apr; 42(5):547-58. PubMed ID: 21371555
[TBL] [Abstract][Full Text] [Related]
9. A duplex oligodeoxynucleotide-dendrimer bioconjugate as a novel delivery vehicle for doxorubicin in in vivo cancer therapy.
Lee IH; Yu MK; Kim IH; Lee JH; Park TG; Jon S
J Control Release; 2011 Oct; 155(1):88-95. PubMed ID: 20854858
[TBL] [Abstract][Full Text] [Related]
10. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy.
Guo XL; Kang XX; Wang YQ; Zhang XJ; Li CJ; Liu Y; Du LB
Acta Biomater; 2019 Jan; 84():367-377. PubMed ID: 30528609
[TBL] [Abstract][Full Text] [Related]
11. Poly(amidoamine) conjugates containing doxorubicin bound via an acid-sensitive linker.
Lavignac N; Nicholls JL; Ferruti P; Duncan R
Macromol Biosci; 2009 May; 9(5):480-7. PubMed ID: 19016501
[TBL] [Abstract][Full Text] [Related]
12. Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy.
Etrych T; Mrkvan T; Ríhová B; Ulbrich K
J Control Release; 2007 Sep; 122(1):31-8. PubMed ID: 17631976
[TBL] [Abstract][Full Text] [Related]
13. Preparation and in vitro characterization of pluronic-attached polyamidoamine dendrimers for drug delivery.
Gu Z; Wang M; Fang Q; Zheng H; Wu F; Lin D; Xu Y; Jin Y
Drug Dev Ind Pharm; 2015 May; 41(5):812-8. PubMed ID: 24745851
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin-PAMAM dendrimer complex attached to liposomes: cytotoxic studies against human cancer cell lines.
Papagiannaros A; Dimas K; Papaioannou GT; Demetzos C
Int J Pharm; 2005 Sep; 302(1-2):29-38. PubMed ID: 16099117
[TBL] [Abstract][Full Text] [Related]
15. The interaction of dendrimer-doxorubicin conjugates with a model pulmonary epithelium and their cosolvent-free, pseudo-solution formulations in pressurized metered-dose inhalers.
Zhong Q; Humia BV; Punjabi AR; Padilha FF; da Rocha SRP
Eur J Pharm Sci; 2017 Nov; 109():86-95. PubMed ID: 28774811
[TBL] [Abstract][Full Text] [Related]
16. Poly(ethylene glycol)-modified PAMAM-Fe3O4-doxorubicin triads with the potential for improved therapeutic efficacy: generation-dependent increased drug loading and retention at neutral pH and increased release at acidic pH.
Nigam S; Chandra S; Newgreen DF; Bahadur D; Chen Q
Langmuir; 2014 Feb; 30(4):1004-11. PubMed ID: 24446987
[TBL] [Abstract][Full Text] [Related]
17. Novel water-soluble and pH-responsive anticancer drug nanocarriers: doxorubicin-PAMAM dendrimer conjugates attached to superparamagnetic iron oxide nanoparticles (IONPs).
Chang Y; Meng X; Zhao Y; Li K; Zhao B; Zhu M; Li Y; Chen X; Wang J
J Colloid Interface Sci; 2011 Nov; 363(1):403-9. PubMed ID: 21821262
[TBL] [Abstract][Full Text] [Related]
18. Polymer conjugates of doxorubicin bound through an amide and hydrazone bond: Impact of the carrier structure onto synergistic action in the treatment of solid tumours.
Etrych T; Subr V; Laga R; Ríhová B; Ulbrich K
Eur J Pharm Sci; 2014 Jul; 58():1-12. PubMed ID: 24632485
[TBL] [Abstract][Full Text] [Related]
19. Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex.
Han M; Lv Q; Tang XJ; Hu YL; Xu DH; Li FZ; Liang WQ; Gao JQ
J Control Release; 2012 Oct; 163(2):136-44. PubMed ID: 22940126
[TBL] [Abstract][Full Text] [Related]
20. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
Wong HL; Rauth AM; Bendayan R; Wu XY
Eur J Pharm Biopharm; 2007 Mar; 65(3):300-8. PubMed ID: 17156986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
